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Abstract
Objective
To validate preoperative dynamic CT and fecal elastase-1 level in predicting the develop-
ment of pancreatic fistulae after pancreatoduodenectomy.
Materials and methods
For 146 consecutive patients, CT attenuation values of the nontumorous pancreatic paren-
chyma were retrospectively measured on precontrast, arterial and equilibrium phase images
for calculation of enhancement ratios. CT enhancement ratios and preoperative fecal elas-
tase-1 levels were correlated with the development of pancreatic fistulae using independent
t-test, logistic regression models, ROC analysis, Youden method and tree analysis.
Results
The mean value of enhancement ratio on equilibrium phase was significantly higher (p =
0.001) in the patients without pancreatic fistula (n = 107; 2.26±3.63) than in the patients with
pancreatic fistula (n = 39; 1.04±0.51); in the logistic regression analyses, it was significant
predictor for the development of pancreatic fistulae (odds ratio = 0.243, p = 0.002). The
mean preoperative fecal elastase-1 levels were higher (odds ratio = 1.003, p = 0.034) in the
pancreatic fistula patients than other patients, but there were no significant differences in
the areas under the curve between the prediction values of CT enhancement ratios and
fecal elastase-1 combined and those of CT enhancement ratios alone (P = 0.897, p = 0.917)
on ROC curve analysis. Tree analysis revealed that the CT enhancement ratio was more
powerful predictor of pancreatic fistula than fecal elastase-1 levels.
Conclusion
The preoperative CT enhancement ratio of pancreas acquired at equilibrium phase regard-
less of combination with fecal elastase-1 levels might be a useful predictor of the risk of
developing a pancreatic fistula following pancreatoduodenectomy.
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Introduction
The rate of mortality following pancreatoduodenectomy (PD), with or without pylorus preser-
vation, has significantly declined over the last decades [1,2]. However, the post-PD morbidity
rate is still high (30–60%) [1–4]. Postoperative pancreatic fistula (POPF) following PD is the
main cause for post-PD morbidity, and results in longer hospital stays, increased costs of hos-
pitalization and treatment, or even death [5–8]. Therefore, identifying patients at high risk for
POPF is important for decreasing the post-PD morbidity and improving the clinical outcome.
In previous studies, several factors including a soft pancreas, pancreatic duct size, fatty pan-
creas and obesity were recognized as the risk factors for POPF [5–11]. Of these factors, the
presence of a ‘soft’ or ‘normal’ pancreatic texture is the most widely accepted risk factor for
developing a pancreatic fistula following PD [5,9,12]. On the other hand, pancreatic fibrosis
with a ‘firm’ or ‘hard’ pancreatic texture is thought to decrease the risk of POPF. Previous stud-
ies have reported that the rate of POPF is low in the fibrotic pancreases with firm parenchyma
[9–11,13].
Therefore, the preoperative assessment of pancreatic fibrosis might be helpful not only in
predicting the development of pancreatic fistulae after PD, but also in preoperative patient
counseling and postoperative management. Thus far, only a few studies have evaluated
whether the degree of pancreatic fibrosis can be reliably estimated and quantified radiologi-
cally [14–18]. On dynamic computed tomography (CT) or magnetic resonance imaging
(MRI), a fibrotic pancreas with autoimmune pancreatitis or chronic pancreatitis shows
delayed enhancement with a slow increase followed by a slow decline or a plateau, whereas a
normal soft pancreas shows rapid enhancement and a rapid decrease [14–18]. On the other
hand, the normal exocrine pancreatic function of the ‘soft’ pancreatic tissue, as compared to
that of the ‘hard’ fibrotic pancreatic tissue in patients with chronic pancreatitis, has been
reported as one of the risk factors for POPF [19,20]. Fecal elastase-1 is a pancreas-specific
enzyme and has been proposed as a suitable marker for pancreatic insufficiency [21–23]. We
hypothesized that the delayed phase images of dynamic CT, which can better reveal parenchy-
mal fibrosis than those acquired at the earlier phases, and the combined evaluation of the pre-
operative CT data and fecal elastase-1 levels could provide more accurate information for
predicting the development of POPF. The aim of this study was to evaluate the stand-alone
and combined abilities of preoperative dynamic CT and fecal elastase-1 levels to predict the
development of pancreatic fistulae after pancreatoduodenectomy.
Materials and methods
This retrospective study was approved by the Gangnam Severance Hospital institutional
review board (IRB) for clinical studies, and the requirement for informed patient consent was
waived.
Patients and clinical data collection
Among the 347 consecutive patients who underwent PD with or without pylorus preserving
surgery between January 2006 and March 2015, 148 patients had medical records of POPF and
pre-operative dynamic CT data available for retrospective analysis. During the preliminary
review of CT, two of the patients were excluded due to the mostly atrophic parenchyma to
draw a region of interest (ROI), which was of at least 3-mm diameter on the CT images. Of the
remaining 146 patients recruited for the data analysis, 82 (56%) were male and 64 (44%) were
female; the mean age of the patient population was 62 years. Fifteen patients had benign dis-
eases (intraductal papillary mucinous neoplasm, 9; solid pseudopapillary tumor, 2; benign
neuroendocrine tumor, 1; serous cystadenoma, 1; chronic pancreatitis, 1; and choledochal
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cyst, 1), and 131 patients had malignant diseases (malignant pancreatic diseases, 45; common
bile duct cancer, 45; ampullary cancer, 40; and duodenal cancer, 1). Preoperative dynamic CT
was performed 1 to 144 days (median 12 days) before pancreatoduodenectomy; besides the six
patients (one benign neuroendocrine tumor, and five intraductal papillary mucinous neo-
plasms; 61 to 144 days), time intervals between the dynamic CT and the operation were within
35 days for all other patients. Meanwhile, 73 out of the 146 patients had medical records of
their preoperative fecal elastase-1 levels to assess exocrine pancreatic function. All of the sam-
ples were collected 4 days preoperatively. The fecal elastase-1 concentrations were measured
using a commercially available enzyme-linked immunoassay (ELISA) kit (Schebo Biotech AG,
Giessen, Germany).
Definition of POPF
Pancreatic fistula was defined by output via an operative drain of any measurable volume of
drain fluid on or after postoperative day 3 with amylase content greater than three times the
upper normal serum level (more than 300 IU/L) according to the definition given by the Inter-
national Study Group on Pancreatic Fistula (ISGPF) [24]. A grade A fistula is transient and
asymptomatic, evident only by elevated drain amylase levels. A grade B leakage necessitates
changes in patient management or adjustments in the clinical treatment plan, including the
introduction of antibiotic therapy, supplemental nutrition, somatostatin analogs, and percuta-
neous drainage. A grade C fistula is the most severe and necessitates major deviations in the
clinical management. Furthermore, a grade C fistula might result in sepsis, organ dysfunction,
and even death and may require surgical exploration for definitive management. For the pur-
pose of this study, the patients were divided into two groups: non- POPF group (n = 107, 73%)
and POPF group (n = 39, 27%) including grade A (n = 26), grade B (n = 9) and grade C (n = 4).
CT protocol
For the 86 out of 146 patients, preoperative dynamic CT was performed using one of two scan-
ners: a 16-slice multidetector CT (MDCT) scanner (Somatom Sensation 16, Siemens Medical
Solutions, Erlangen, Germany), or a 64-slice MDCT scanner (Somatom Sensation 64, Siemens
Medical Solutions, Erlangen, Germany). All the patients were instructed to fast for at least 5
hours before they underwent CT examination. Each patient was administered 150 mL of a
nonionic contrast material (Ultravist 300, Schering AG, Berlin, Germany) intravenously by
means of a power injector (EnVision CT, Medrad, Pittsburgh, Pa) at a rate of 3 mL/second.
The CT images were acquired in a craniocaudal direction with the following parameters: de-
tector collimation, 16 × 0.75 mm; table feed, 12 mm per rotation; section width, 3 mm; recon-
struction increment, 3 mm with 3-mm-thick sections; pitch, 1.2; tube voltage, 120 kVp; and
tube current, 160 mAs. Precontrast (Pre) scanning (i.e., the first pass) was performed first, fol-
lowed by contrast-enhanced CT. In order to determine the time of peak aortic enhancement, a
bolus injection of 20 mL of contrast material was administered, and sequential dynamic sec-
tions were acquired every 2 seconds, starting from the hepatic hilum. Based on the findings of
a previous study on multidetector row helical CT, we calculated the start time for the arterial
phase (AP) by adding 15 seconds to the time of peak aortic enhancement calculated at the
hepatic hilum. The ensuing average start time for the arterial phase was 34 seconds (range, 30–
38 seconds). The portal venous phase scan was acquired at 70 seconds after the start of the con-
trast material injection. The equilibrium phase (EP) scan was acquired at 3 minutes after the
start of the contrast material injection. Since our institute was a tertiary referral hospital, and
there were many patients referred here from other institutes, CT data of other 60 patients were
acquired at other hospitals using non-unified dynamic imaging protocols.
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Data analysis
Two radiologists, blinded to the patients’ clinical data, analyzed the preoperative CT images.
The CT attenuation values of the pancreatic parenchyma were measured on the unenhanced
images and the images obtained in the arterial and equilibrium phases after contrast adminis-
tration, by placing the ROI in the pancreas over the superior mesenteric vein in an area unaf-
fected by the tumor. The largest possible circular or oval ROI was placed with every effort to
avoid the pancreatic mass, pancreatic duct, and partial volume averaging from the extrapan-
creatic structures. The smallest ROI was approximately 3 mm in diameter in cases where the
pancreatic parenchyma was atrophic. The mean value of the CT attenuations were calculated,
and the three attenuation parameters were calculated as follows: (AP–Pre)/Pre, (EP–Pre)/Pre
and (EP–Pre)/(AP–Pre) (Fig 1).
Statistical analysis
The mean CT attenuation values and fecal elastase-1 levels of the patients with POPF (grade A,
B, or C) and those of the patients without POPF were compared using the independent two-
sample t-test. Logistic regression models were used to evaluate the risk factors for the develop-
ment of POPF for univariate analysis. To evaluate the efficacy of the risk factors in the predic-
tion of POPF development and to establish the optimal cut-off points, the receiver operating
characteristic (ROC) curve and Youden analyses were performed. The ROC comparison was
performed to compare the ability of the clinical cut-off value of fecal elastase-1 to discriminate
the POPF from non-POPF cases with that of the cut-off value obtained using the Youden
method. For the combined assessment of the ability of the CT and fecal elastase-1 findings
to predict POPF development, the ROC comparison and tree analysis were performed. A
p-value <0.05 was considered statistically significant. All of the statistical calculations were
performed using the SAS software (release 9.2; SAS Institute Inc., Cary, NC, USA).
Results
The mean values of (AP–Pre)/Pre show a decreasing trend with the increase in the grade of
POPF (Table 1). The mean values of (EP–Pre)/Pre and (EP–Pre)/(AP–Pre) also show a
Fig 1. Measurement of pancreatic parenchymal attenuation density with ROI (region of interest). A, B.
Comparing to normal pancreatic parenchyma (A), fibrotic pancreas (B) shows gradually increased and higher
attenuation densities at the same ROI. Pre, pre-contrast; AP, arterial phase; EP, equilibrium phase.
https://doi.org/10.1371/journal.pone.0177052.g001
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decreasing trend with the increase in the grade of POPF (Table 1). In the non-POPF group,
the pancreas showed delayed enhancement compared to the pancreatic enhancement pattern
seen in the POPF group. Therefore, the mean values of (EP–Pre)/Pre and (EP–Pre)/(AP–Pre)
of the non-POPF group were significantly higher than those of the POPF group (2.26±3.63 vs.
1.04±0.51; p = 0.001 and 1.12±1.40 vs. 0.71±0.29; p = 0.006, respectively). In logistic regression
analyses, the values of (EP–Pre)/Pre and (EP–Pre)/(AP–Pre) were found to be significant pre-
dictors for the development of pancreatic fistula (odds ratio (OR) = 0.243, p = 0.002 and OR =
0.176, p = 0.014, respectively). The optimal cut-off point of (EP–Pre)/Pre for the discrimina-
tion of the patients developing POPF from those without POPF was determined to be 1.100
(areas under the curve [AUC], 0.749; sensitivity, 77%; and specificity, 69%) and that of (EP–
Pre)/(AP–Pre) was determined to be 0.60 (AUC, 0.684; sensitivity, 51%; and specificity, 81%)
(Fig 2).
Of the 73 patients whose records of preoperative fecal elastase-1 levels were available, 21
(29%) developed POPF (grade A, 15; grade B, 4; and grade C, 2). The non-POPF group was
composed of the remaining 52 patients. The mean preoperative fecal elastase-1 level of the
POPF group was significantly higher than that of the non-POPF group (359.4 vs. 252.0; p =
0.029). In the logistic regression analyses, fecal elastase-1 was a marginally meaningful predic-
tive factor of pancreatic fistula (OR = 1.003, p = 0.034). According to the ROC curve and You-
den analyses, the AUC was 0.657 (95% CI, 0.536–0.764) and the optimal cut-off point for the
discrimination of the patients with POPF from those without POPF was 120.1 (sensitivity,
95%; specificity, 38%) (Fig 3). Clinically, fecal elastase-1 values greater than 200μg/g stool
Table 1. Mean values of the three CT attenuation ratios according to the POPF grade.
Calculated parameters Non-POPF Grade A Grade B Grade C Mean values
(n = 107) (n = 26) (n = 9) (n = 4)
(AP–Pre)/Pre 2.08 ± 1.53 1.56 ± 0.80 1.59 ± 0.47 1.24 ± 0.33 1.93 ± 1.38
(EP–Pre)/Pre 2.26 ± 3.63 1.02 ± 0.55 1.19 ± 0.47 0.82 ± 0.20 1.93 ± 3.16
(EP–Pre)/(AP–Pre) 1.12 ± 1.40 0.70 ± 0.30 0.77 ± 0.35 0.67 ± 0.11 1.01 ± 1.22
AP, arterial phase; Pre, pre-contrast; EP, equilibrium phase.
https://doi.org/10.1371/journal.pone.0177052.t001
Fig 2. Receiver operating characteristic (ROC) curve of the CT attenuation ratios. Pre, pre-contrast; AP,
arterial phase; EP, equilibrium phase.
https://doi.org/10.1371/journal.pone.0177052.g002
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indicate normal exocrine pancreatic function and those 200μg/g stool suggest exocrine pan-
creatic insufficiency [22]. In the ROC comparison of the ability of the clinical cut-off value
(200μg/g stool) and that of the cut-off value obtained using the Youden method (120μg/g
stool), to discriminate the patients with POPF from those without, the value of AUC was
slightly higher when the cut-off point was 120μg/g stool; however, there was no statistically
significant difference between the predictive abilities of the two (AUC = 0.669 for cut-off
point = 120μg/g stool; AUC = 0.636 for cut-off point = 200μg/g stool; p = 0.447) (Fig 4).
Of the 73 patients with available preoperative dynamic CT and fecal elastase-1 level records,
the AUC values of the stand-alone CT enhancement ratios were slightly higher than those of
the combination of the CT enhancement ratios and fecal elastase-1 levels; however, there were
no statistically significant difference (AUC = 0.729 for (EP–Pre)/Pre; AUC = 0.726 for the
combination of (EP–Pre)/Pre and fecal elastase-1 levels; p = 0.897 and AUC = 0.720 for (EP–
Pre)/(AP–Pre); AUC = 0.716 for the combination of (EP–Pre)/(AP–Pre) and fecal elastase-1
levels; p = 0.917) (Fig 5).
A tree analysis was performed to evaluate the efficacy of the CT enhancement ratios and
fecal elastase-1 levels for the prediction of POPF and to establish their cut- off values when
evaluated in conjunction (Fig 6). In the tree analysis of the (EP–Pre)/Pre values and fecal elas-
tase-1 levels on conjunction, the CT enhancement ratio was the more powerful tool for the
prediction of POPF. At (EP–Pre)/Pre values1.11, the non-occurrence of POPF could be
Fig 3. ROC curve of the fecal elastase-1 levels.
https://doi.org/10.1371/journal.pone.0177052.g003
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expected regardless of the fecal elastase-1 levels; at (EP–Pre)/Pre values less than 0.72, POPF
could be expected to develop regardless of the fecal elastase-1 levels; and at (EP–Pre)/Pre values
between 0.72 and 1.11, fecal elastase-1 levels could help predict the development of POPF. In
Fig 4. ROC curve for the comparison of the fecal elastase-1 levels at the cut-off points of 120.1μg/g
stool and 200 μg/g stool.
https://doi.org/10.1371/journal.pone.0177052.g004
Fig 5. ROC curve for the comparison of the abilities of the CT enhancement ratios alone and the
combination of CT enhancement ratios and fecal elastase-1 levels to predict postoperative pancreatic
fistulae. Pre, pre-contrast; AP, arterial phase; EP, equilibrium phase.
https://doi.org/10.1371/journal.pone.0177052.g005
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the tree analysis of the (EP–Pre)/(AP–Pre) values and fecal elastase-1 levels in conjuction, the
efficacy of the latter for POPF prediction could be ignored. At (EP–Pre)/(AP–Pre) values
>0.60, the non-occurrence of POPF could be expected regardless of the fecal elastase-1 levels.
Discussion
The mortality rate associated with pancreatoduodenectomy has decreased to less than 5% due
to advances in the postoperative care and surgical techniques [5,12,25–32]. However, the mor-
bidity still remains high, with a rate of 30–60%, and is often related to the occurrence of POPF
[6–8]. The risk factors for the development of pancreatic fistula after PD have been extensively
studied [5–10,12,25,26,28,30–33]. The presence of soft pancreatic parenchyma is the most
widely recognized of those risk factors [5,9,12]. On the other hand, the presence of pancreatic
fibrosis with a firm pancreatic texture is thought to decrease the risk of POPF development
[4–18,34]. Therefore, the preoperative assessment of pancreatic fibrosis might be helpful in
predicting POPF and in pre- and post-operative management. When identifying high risk
patients for pancreatic fistula accurately and easily with preoperative assessment of pancreatic
fibrosis, protocols for administration of perioperative pasireotide, a somatostatin analogue
that decreases the rate of clinically significant pancreatic fistula, would be clearly guided to
maximizing cost-efficacy in high risk patients [35, 36].
Recent studies have shown that CT or MRI perfusion imaging can detect the microcircula-
tory changes caused by collagen deposition in the pancreas [14–16,18]. These studies have
shown that pancreatic fibrosis is characterized by delayed enhancement with a slow rise to the
peak, followed by a slow decline or plateau, while the normal pancreas shows a rapid rise to
the peak, followed by a rapid decline. Only a few studies have described the quantitative assess-
ment of the pancreatic enhancement characteristics on the preoperative CT or MRI, as a
method to estimate the risk of developing POPF. Dinter et al. calculated a muscle-normalized
signal intensity (SI) curve with a SI ratio using dynamic contrast-enhanced MRI in 72 pa-
tients who underwent PD by duct-to-mucosa pancreatojejunostomy [14]. The SI ratios were
grouped into two groups: rapid increase (SI ratio1.1; early arterial value > portal-venous
value; soft pancreas) and equilibrium increase (SI ratio <1.1; firm or hard pancreas) groups.
In multivariate analysis, the SI ratio1.1 was the only preoperative parameter that could pre-
dict the leakage. Using a dual-phase pancreatic CT technique, Hashimoto et al. expressed the
Fig 6. Tree analysis of the abilities of the CT enhancement ratios and fecal elastase-1 levels to predict
postoperative pancreatic fistulae. Pre, pre-contrast; AP, arterial phase; EP, equilibrium phase.
https://doi.org/10.1371/journal.pone.0177052.g006
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late phase/early phase ratio (L/E ratio), calculated as (hepatic phase—unenhanced phase)/
(pancreatic phase—unenhanced phase), to indicate delayed phase enhancement [37]. The L/E
ratio and histological grade of pancreatic fibrosis were correlated with the development of a
clinically relevant pancreatic anastomotic failure (PAF) and the other clinical parameters. In
the multivariate analyses, the L/E ratio and body mass index (BMI) were found to be signifi-
cant predictors for the development of a clinically relevant PAF.
In the present study, we expected that the mean value of (AP–Pre)/Pre of the POPF group
would be higher than that of the non-POPF group. However, the actual result obtained was
different from what was expected. Commonly, the pancreatic phase scans are acquired 40–70
seconds after the infusion of the intravenous contrast material, at which time, the tumor-to-
pancreas attenuation difference is the greatest [38,39]. In the previous studies, that evaluated
the enhancement patterns of the normal pancreas and the fibrotic pancreas with autoimmune
pancreatitis or chronic pancreatitis, the early images of the pancreatic enhancement peak were
obtained 25–45 seconds after the administration of the contrast material [15,17,18,40,41]. In
this narrow time range of barely dozens of seconds, the time-attenuation curve showed a steep
slope. Therefore, it is possible that the values of pancreatic attenuation vary significantly with
the time differences of just a few seconds during the narrowing of the time range. Further-
more, in the study of Tajima et al., the time-signal intensity curve (TIC) of the fibrotic pancreas
showed a slow rise to the peak value at 1–2 min after the administration of contrast material
[17]. The recruited patients in the present study included a number of patients referred from
other hospitals, which caused discrepancies in the obtaining of the early phase images for the
dynamic imaging protocol. It was, therefore, difficult to measure the attenuation value of the
pancreas at the arterial phase in all of the cases at a standardized time. Given this situation, it
was difficult to obtain as reliable result as was expected using the arterial image data. Mean-
while, in order to express the delayed enhancement corresponding to pancreatic fibrosis, we
used a 3-min delayed CT attenuation value after contrast administration, and calculated two
enhancement ratios, (EP–Pre)/Pre and (EP–Pre)/(AP–Pre), while previous studies mentioned
above used CT attenuation values of hepatic or portal-venous phases 60–70 sec after the
administration of the contrast material [14,37]. In most studies, the time-attenuation curve
showed a plateau or gradual slope during the 3-min delay after contrast administration with
higher attenuation values in the fibrotic pancreas compared to those in the normal pancreas
[15,17,18,40,41]. Therefore, there would be no remarkable differences between the pancreatic
attenuation values based on the difference of a few or dozens of seconds. Furthermore, in the
various dynamic CT protocols of different hospitals, there were slight differences in the images
of the AP or portal venous phases, but the EP images were acquired approximately 3 min after
contrast administration, in most cases. Therefore, using the 3-min delayed CT attenuation val-
ues to express the delayed enhancement corresponding to pancreatic fibrosis seems reasonable
in practice. Pancreatic fibrosis causes the loss of the exocrine function of the pancreas. There
have been several studies reporting that a soft pancreas has a good exocrine function and
secretes more pancreatic juices, which contain proteolytic enzymes [42,43]. Therefore, the exo-
crine pancreatic function would most probably be correlated with pancreatic fibrosis, and
could be used to preoperatively predict POPF development. Human fecal elastase-1 is a pan-
creas-specific proteolytic enzyme, not degraded during intestinal transport and reaches con-
centrations in feces 5–6 times those in the duodenal juice, and has been proposed as a suitable
marker for pancreatic insufficiency [21–23]. The measurement of fecal elastase-1 levels by
ELISA is sensitive, specific, and noninvasive [44,45]. In the present study, the fecal elastase-1
level was a statistically significant predictive factor of pancreatic fistula; but, there were no
great differences in the AUC values between the CT enhancement ratios and fecal elastase-1
levels in conjunction and the CT enhancement ratios alone. This indicates that there is no
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added benefit in using the CT enhancement ratios in conjunction with the fecal elastase-1 lev-
els for the discrimination of the patients with POPF from those without. It is thought that
these results are probably related to the relatively low odd ratios of the fecal elastase-1 levels.
There were some limitations to this study. Firstly, because of the retrospective nature of our
study, there were no reference standards of the pathological fibrosis data to correlate with the
CT enhancement ratios or fecal elastase-1 levels for the validation of our results. Secondly, the
number of patients with the records of fecal elastase-1 levels available was quite small; this
might be a reason for the low odd ratios of fecal elastase-1 levels, which resulted in a negligible
combined predictive value of the two preoperative predictive tools of POPF. Thirdly, because
postoperative pancreatic stent (P-J stent) was routinely used in all subjected patients, we did
not concern the effect of the stent related to the incidence of POPF. We just presumed that low
incidence of POPF in the recruited patients’ group in the present study might be related to the
use of postoperative P-J stent [46]. With the low incidence of post-operative pancreatic fistula,
the value of fecal elastase-1 might be rather limited comparing to the prior reports; however,
there were no controlled data for the use of P-J stents, the relationship between the P-J stent
and pre-operative fecal elastase could not be discussed here. Finally, the number of patients
with grade C POPF was too small to separate the analysis of the correlation between the CT
enhancement ratios/fecal elastase-1 levels and the POPF grades according to the clinical sever-
ity. However, we showed the decreasing trend of the mean values of the CT enhancement
ratios according to the POPF grade.
In conclusion, depending on the relationship between the delayed enhancement of the pan-
creatic parenchyma on dynamic CT and the absence of POPF without remarkable added bene-
fit of combining the fecal elastase-1 levels, CT enhancement ratios acquired at EP regardless of
fecal elastase-1 data can be used as a reliable predictor of the risk of developing a POPF.
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(XLS)
Author Contributions
Conceptualization: JSP JSY.
Data curation: DSY.
Formal analysis: J. Kang.
Investigation: J. Kang JSP JSY.
Methodology: J. Kang JSY.
Resources: JSP DSY.
Validation: JJC J. Kim ESC.
Visualization: DSY.
Writing – original draft: J. Kang.
Writing – review & editing: J. Kang JSY.
Prediction of post-pancreatoduodenectomy pancreatic fistula by dynamic CT and fecal elastase-1
PLOS ONE | https://doi.org/10.1371/journal.pone.0177052 May 11, 2017 10 / 13
References
1. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pan-
creaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J
Surg 2003; 27:324–9. https://doi.org/10.1007/s00268-002-6659-z PMID: 12607060
2. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections
without an operative mortality. Ann Surg 1990; 211:447–58. PMID: 2322039
3. Adam U, Makowiec F, Riediger H, Schareck WD, Benz S, Hopt UT. Risk factors for complications after
pancreatic head resection. Am J Surg 2004; 187:201–8. https://doi.org/10.1016/j.amjsurg.2003.11.004
PMID: 14769305
4. DeOliveira ML, Winter JM, Schafer M, Cunningham SC, Cameron JL, Yeo CJ, et al. Assessment of
complications after pancreatic surgery: A novel grading system applied to 633 patients undergoing pan-
creaticoduodenectomy. Ann Surg 2006; 244:931–7; discussion 7–9. https://doi.org/10.1097/01.sla.
0000246856.03918.9a PMID: 17122618
5. Hashimoto Y, Traverso LW. Incidence of pancreatic anastomotic failure and delayed gastric emptying
after pancreatoduodenectomy in 507 consecutive patients: Use of a web-based calculator to improve
homogeneity of definition. Surgery 2010; 147:503–15. https://doi.org/10.1016/j.surg.2009.10.034
PMID: 20018335
6. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, Nakagawa N, et al. No mortality after
150 consecutive pancreatoduodenctomies with duct-to-mucosa pancreaticogastrostomy. J Surg Oncol
2008; 97:205–9. https://doi.org/10.1002/jso.20903 PMID: 18050288
7. Poon RT, Fan ST, Lo CM, Ng KK, Yuen WK, Yeung C, et al. External drainage of pancreatic duct with a
stent to reduce leakage rate of pancreaticojejunostomy after pancreaticoduodenectomy: a prospective
randomized trial. Ann Surg 2007; 246:425–33; discussion 33–5. https://doi.org/10.1097/SLA.
0b013e3181492c28 PMID: 17717446
8. Pratt WB, Maithel SK, Vanounou T, Huang ZS, Callery MP, Vollmer CM Jr. Clinical and economic vali-
dation of the International Study Group of Pancreatic Fistula (ISGPF) classification scheme. Ann Surg
2007; 245:443–51. https://doi.org/10.1097/01.sla.0000251708.70219.d2 PMID: 17435552
9. Lin JW, Cameron JL, Yeo CJ, Riall TS, Lillemoe KD. Risk factors and outcomes in postpancreaticoduo-
denectomy pancreaticocutaneous fistula. J Gastrointest Surg 2004; 8:951–9. https://doi.org/10.1016/j.
gassur.2004.09.044 PMID: 15585382
10. Hashimoto Y, Traverso LW. Pancreatic anastomotic failure rate after pancreaticoduodenectomy
decreases with microsurgery. J Am Coll Surg 2010; 211:510–21. https://doi.org/10.1016/j.jamcollsurg.
2010.06.018 PMID: 20801693
11. Yeo CJ, Cameron JL, Lillemoe KD, Sauter PK, Coleman J, Sohn TA, et al. Does prophylactic octreotide
decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy?
Results of a prospective randomized placebo-controlled trial. Ann Surg 2000; 232:419–29. PMID:
10973392
12. Yeo CJ, Cameron JL, Maher MM, Sauter PK, Zahurak ML, Talamini MA, et al. A prospective random-
ized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy.
Ann Surg 1995; 222:580–8; discussion 8–92. PMID: 7574936
13. Nakamura H, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Ohge H, et al. Predictive factors for exo-
crine pancreatic insufficiency after pancreatoduodenectomy with pancreaticogastrostomy. J Gastroint-
est Surg 2009; 13:1321–7. https://doi.org/10.1007/s11605-009-0896-5 PMID: 19415402
14. Dinter DJ, Aramin N, Weiss C, Singer C, Weisser G, Schoenberg SO, et al. Prediction of anastomotic
leakage after pancreatic head resections by dynamic magnetic resonance imaging (dMRI). J Gastroint-
est Surg 2009; 13:735–44. https://doi.org/10.1007/s11605-008-0765-7 PMID: 19057965
15. Kim T, Murakami T, Takamura M, Hori M, Takahashi S, Nakamori S, et al. Pancreatic mass due to
chronic pancreatitis: correlation of CT and MR imaging features with pathologic findings. AJR Am J
Roentgenol 2001; 177:367–71. https://doi.org/10.2214/ajr.177.2.1770367 PMID: 11461864
16. Lee SE, Jang JY, Lim CS, Kang MJ, Kim SH, Kim MA, et al. Measurement of pancreatic fat by magnetic
resonance imaging: predicting the occurrence of pancreatic fistula after pancreatoduodenectomy. Ann
Surg 2010; 251:932–6. https://doi.org/10.1097/SLA.0b013e3181d65483 PMID: 20395858
17. Tajima Y, Matsuzaki S, Furui J, Isomoto I, Hayashi K, Kanematsu T. Use of the time-signal intensity
curve from dynamic magnetic resonance imaging to evaluate remnant pancreatic fibrosis after pancrea-
ticojejunostomy in patients undergoing pancreaticoduodenectomy. Br J Surg 2004; 91:595–600. https://
doi.org/10.1002/bjs.4461 PMID: 15122611
18. Takahashi N, Fletcher JG, Hough DM, Fidler JL, Kawashima A, Mandrekar JN, et al. Autoimmune pan-
creatitis: differentiation from pancreatic carcinoma and normal pancreas on the basis of enhancement
Prediction of post-pancreatoduodenectomy pancreatic fistula by dynamic CT and fecal elastase-1
PLOS ONE | https://doi.org/10.1371/journal.pone.0177052 May 11, 2017 11 / 13
characteristics at dual-phase CT. AJR Am J Roentgenol 2009; 193:479–84. https://doi.org/10.2214/
AJR.08.1883 PMID: 19620446
19. Niedergethmann M, Farag Soliman M, Post S. Postoperative complications of pancreatic cancer sur-
gery. Minerva Chir 2004; 59:175–83. PMID: 15238891
20. Murakami H, Suzuki H, Nakamura T. Pancreatic fibrosis correlates with delayed gastric emptying after
pylorus-preserving pancreaticoduodenectomy with pancreaticogastrostomy. Ann Surg 2002; 235:240–
5. PMID: 11807364
21. Glasbrenner B, Schon A, Klatt S, Beckh K, Adler G. Clinical evaluation of the faecal elastase test in the
diagnosis and staging of chronic pancreatitis. Eur J Gastroenterol Hepatol 1996; 8:1117–20. PMID:
8944376
22. Loser C, Mollgaard A, Folsch UR. Faecal elastase 1: a novel, highly sensitive, and specific tubeless
pancreatic function test. Gut 1996; 39:580–6. PMID: 8944569
23. Stein J, Jung M, Sziegoleit A, Zeuzem S, Caspary WF, Lembcke B. Immunoreactive elastase I: clinical
evaluation of a new noninvasive test of pancreatic function. Clin Chem 1996; 42:222–6. PMID: 8595714
24. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an
international study group (ISGPF) definition. Surgery 2005; 138:8–13. https://doi.org/10.1016/j.surg.
2005.05.001 PMID: 16003309
25. Cameron JL, Pitt HA, Yeo CJ, Lillemoe KD, Kaufman HS, Coleman J. One hundred and forty-five con-
secutive pancreaticoduodenectomies without mortality. Ann Surg 1993; 217:430–5; discussion 5–8.
PMID: 8098202
26. Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, et al. A prospective randomized
trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lym-
phadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005; 138:618–28; discussion
28–30. https://doi.org/10.1016/j.surg.2005.06.044 PMID: 16269290
27. Lillemoe KD, Cameron JL, Kim MP, Campbell KA, Sauter PK, Coleman JA, et al. Does fibrin glue seal-
ant decrease the rate of pancreatic fistula after pancreaticoduodenectomy? Results of a prospective
randomized trial. J Gastrointest Surg 2004; 8:766–72; discussion 72–4. https://doi.org/10.1016/j.
gassur.2004.06.011 PMID: 15531229
28. Lowy AM, Lee JE, Pisters PW, Davidson BS, Fenoglio CJ, Stanford P, et al. Prospective, randomized
trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease.
Ann Surg 1997; 226:632–41. PMID: 9389397
29. Marcus SG, Cohen H, Ranson JH. Optimal management of the pancreatic remnant after pancreatico-
duodenectomy. Ann Surg 1995; 221:635–45; discussion 45–8. PMID: 7794068
30. Pedrazzoli S, Liessi G, Pasquali C, Ragazzi R, Berselli M, Sperti C. Postoperative pancreatic fistulas:
preventing severe complications and reducing reoperation and mortality rate. Ann Surg 2009; 249:97–
104. https://doi.org/10.1097/SLA.0b013e31819274fe PMID: 19106683
31. Roder JD, Stein HJ, Bottcher KA, Busch R, Heidecke CD, Siewert JR. Stented versus nonstented pan-
creaticojejunostomy after pancreatoduodenectomy: a prospective study. Ann Surg 1999; 229:41–8.
PMID: 9923798
32. Sarr MG. The potent somatostatin analogue vapreotide does not decrease pancreas-specific complica-
tions after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-
controlled trial. J Am Coll Surg 2003; 196:556–64; discussion 64–5; author reply 65. https://doi.org/10.
1016/S1072-7515(03)00104-2 PMID: 12691930
33. Friess H, Malfertheiner P, Isenmann R, Kuhne H, Beger HG, Buchler MW. The risk of pancreaticointest-
inal anastomosis can be predicted preoperatively. Pancreas 1996; 13:202–8. PMID: 8829190
34. Hamanaka Y, Nishihara K, Hamasaki T, Kawabata A, Yamamoto S, Tsurumi M, et al. Pancreatic juice
output after pancreatoduodenectomy in relation to pancreatic consistency, duct size, and leakage. Sur-
gery 1996; 119:281–7. PMID: 8619183
35. Allen PJ. Pasireotide for postoperative pancreatic fistula. N Engl J Med 2014; 370:2014–2022. https://
doi.org/10.1056/NEJMoa1313688 PMID: 24849084
36. Ma LW. The Cost of Postoperative Pancreatic Fistula Versus the Cost of Pasireotide: Results from a
Prospective Randomized Trial. Ann Surg 2016.
37. Hashimoto Y, Sclabas GM, Takahashi N, Kirihara Y, Smyrk TC, Huebner M, et al. Dual-phase com-
puted tomography for assessment of pancreatic fibrosis and anastomotic failure risk following pancrea-
toduodenectomy. J Gastrointest Surg 2011; 15:2193–204. https://doi.org/10.1007/s11605-011-1687-3
PMID: 21948179
38. Lu DS, Vedantham S, Krasny RM, Kadell B, Berger WL, Reber HA. Two-phase helical CT for pancreatic
tumors: pancreatic versus hepatic phase enhancement of tumor, pancreas, and vascular structures.
Radiology 1996; 199:697–701. https://doi.org/10.1148/radiology.199.3.8637990 PMID: 8637990
Prediction of post-pancreatoduodenectomy pancreatic fistula by dynamic CT and fecal elastase-1
PLOS ONE | https://doi.org/10.1371/journal.pone.0177052 May 11, 2017 12 / 13
39. Fletcher JG, Wiersema MJ, Farrell MA, Fidler JL, Burgart LJ, Koyama T, et al. Pancreatic malignancy:
value of arterial, pancreatic, and hepatic phase imaging with multi-detector row CT. Radiology 2003;
229:81–90. https://doi.org/10.1148/radiol.2291020582 PMID: 14519871
40. Irie H, Honda H, Baba S, Kuroiwa T, Yoshimitsu K, Tajima T, et al. Autoimmune pancreatitis: CT and
MR characteristics. American Journal of Roentgenology 1998; 170:1323–7. https://doi.org/10.2214/ajr.
170.5.9574610 PMID: 9574610
41. Kawamoto S, Siegelman SS, Hruban RH, Fishman EK. Lymphoplasmacytic Sclerosing Pancreatitis
with Obstructive Jaundice: CT and Pathology Features. American Journal of Roentgenology 2004;
183:915–21. https://doi.org/10.2214/ajr.183.4.1830915 PMID: 15385281
42. Suzuki Y, Fujino Y, Tanioka Y, Hiraoka K, Takada M, Ajiki T, et al. Selection of pancreaticojejunostomy
techniques according to pancreatic texture and duct size. Arch Surg 2002; 137:1044–7; discussion 8.
PMID: 12215157
43. Sato N, Yamaguchi K, Chijiiwa K, Tanaka M. Risk analysis of pancreatic fistula after pancreatic head
resection. Arch Surg 1998; 133:1094–8. PMID: 9790207
44. Sziegoleit A, Linder D. Studies on the sterol-binding capacity of human pancreatic elastase 1. Gastroen-
terology 1991; 100:768–74. PMID: 1993499
45. Katschinski M, Schirra J, Bross A, Goke B, Arnold R. Duodenal secretion and fecal excretion of pancre-
atic elastase-1 in healthy humans and patients with chronic pancreatitis. Pancreas 1997; 15:191–200.
PMID: 9260205
46. Dong Z, Xu J, Wang Z, Petrov MS. Stents for the prevention of pancreatic fistula following pancreatico-
duodenectomy. Cochrane Database Syst Rev 2016 May 6;(5):CD008914. Review. https://doi.org/10.
1002/14651858.CD008914.pub3 PMID: 27153248
Prediction of post-pancreatoduodenectomy pancreatic fistula by dynamic CT and fecal elastase-1
PLOS ONE | https://doi.org/10.1371/journal.pone.0177052 May 11, 2017 13 / 13
